Background: Advanced-stage neuroblastoma patients require multiagent chemotherapy. Intratumoral implantation of vincristine-loaded silk gel uses local diffusion to decrease orthotopic neuroblastoma tumor growth in mice. We hypothesize that injecting vincristine-loaded silk gel into 8 locations within the tumor, instead of only centrally, decreases the diffusion distance and improves tumor growth suppression. Methods: Human neuroblastoma cells, KELLY, were injected into mouse adrenal glands to create orthotopic tumors. After the tumors reached 100 mm 3 by ultrasound, silk gels loaded with 50 μg vincristine were injected centrally or in 8 areas throughout the tumor. Drug-release profile was measured in vitro. Endpoints were tumor size > 1,0 0 0 mm 3 and histologic examination. Results: Vincristine-loaded silk gels suppressed tumor growth up to an inflection point (458.7 ± 234.4 mm 3 for central, 514.3 ± 165.8 mm 3 for 8-point injection) before tumor growth accelerated > 200 mm 3 over 3 days. The time to inflection point was 6.6 days for central, 13.3 days for 8-point injection ( P < .05). Using the sphere volume equation to approximate tumor volume, splitting the volume into 1/8 decreased the diffusion radius by 1/2. Histologic examination confirmed tumor necrosis adjacent to vincristine-loaded silk gel. Conclusion: Injecting vincristine-loaded sustained release silk gel at 8 separate locations halved the diffusion distance and doubled the time for the tumor to reach the growth inflexion point.
Introduction
Neuroblastoma is the most common intra-abdominal solid tumor affecting children; it has remarkably heterogeneous clinical presentations and accounts for 15% of all pediatric cancerrelated deaths. 1, 2 Although the mainstay treatment for low-risk disease is surgical resection, 3 patients with high-risk disease are treated with an aggressive, multimodal approach. Multiagent systemic chemotherapy can include doxorubicin, vincristine, cy-clophosphamide, cisplatin, topotecan, and etoposide. 2 Despite advances in surgical techniques, chemotherapy, radiotherapy, and immunotherapy, survival rate for children with advanced-stage neuroblastoma is still less than 50%. 4 Furthermore, toxicity from systemic chemotherapy results in significant patient morbidity, including renal toxicity, myelosuppression, cardiotoxicity, and longterm complications such as secondary malignancy. 5 The development of novel drug delivery systems that can maximize tumor cell death and minimize systemic side effects is essential for improving outcomes for pediatric patients. [6] [7] [8] We previously used sustained-release silk delivery platforms to treat orthotopic neuroblastoma mouse xenografts by implanting the platform into the center of the tumor. 9 This treatment strategy resulted in significant decreases in tumor growth as well as reductions in systemic toxicity compared with delivering the same dose intravenously.
Using our orthotopic neuroblastoma xenograft model, 9 we aimed to improve tumor growth suppression by altering the diffusion parameters. We engineered sustained-release silk gels loaded https://doi.org/10.1016/j.surg.2018.06.017 0039-6060/© 2018 Elsevier Inc. All rights reserved.
with vincristine that were injected either centrally or throughout the tumor. We hypothesized that tumor growth would be more significantly suppressed by distributed injections compared with central injections of vincristine-loaded silk gel, as a consequence of decreased diffusion distances.
Methods

Silk fibroin extract
Silk fibroin from Bombyx mori silkworm cocoons was extracted as previously described. 10 Briefly, cocoons were cut into approximate 1 cm 2 pieces and boiled in 0.02 M NaCO 3 for 30 minutes to extract the sericin protein. The silk fibroin fibers were dried overnight and then dissolved in 9.3 M LiBr solution for 3 hours at 60 °C. The silk fibroin solution was then dialyzed (3.4 kDa MWCO dialysis cassettes, Thermo Fisher Scientific, Waltham, MA) against ultrapure water at room temperature for 2 days with 7 water changes resulting in an approximately 6.5% (w/v) aqueous silk fibroin solution. The silk fibroin solution was stored at 4 °C for later use.
Vincristine-loaded silk gel
Silk fibroin gel was prepared as previously described. 9 Briefly, the silk solution as described earlier was sterile filtered. Then 2 mL of the prepared solution was sonicated using a Branson Digital Sonifier 450 (Branson Ultrasonics, Danbury, CT) at 10% amplitude for 15 seconds, placed on ice for 2 minutes, and sonicated 1 additional time. Twenty microliters of the pregelled solution was aspirated into a 0.5 mL insulin syringe and allowed to gel at 60 °C. A solution of 60 min extracted silk was prepared at 6.85% (w/v) and sterile filtered. Two milliliters of the prepared solution was sonicated at 15% amplitude for 30 seconds and placed on ice. Vincristine from a 5 mg/mL (125μL) stock was added to the pregelled silk solution (875 μL) to achieve a final concentration of 625 μg/mL vincristine and 6% (w/v) silk. Eighty microliters of the vincristineloaded pregel was aspirated into the previously prepared syringes and allowed to gel at room temperature overnight. The final vincristine amount was 50 μg per syringe; the total dose of injected vincristine was 50 μg per mouse in the treatment groups.
Vincristine release characterization
In vitro release studies were performed under sink conditions where "the volume of medium at least ten times that required in order to form a saturated solution of drug substance." 11 Vincristine-loaded drug delivery systems were placed into 1 mL of phosphate buffered saline (PBS, pH 7.4 Life Technologies, Grand Island, NY) at 37 °C for release quantification. At each time point, the PBS was completely removed and replaced with fresh PBS. The drug concentration was determined via ultraviolet/visible light spectroscopy (SpectraMax M2 spectrophotometer; Molecular Devices, Sunnyvale, CA). A standard curve for vincristine using an absorbance wavelength of 298 nm was generated to determine the vincristine concentration within the release medium. Blank gel samples were used for control readings.
Cell culture
Human neuroblastoma KELLY cells (Sigma-Aldrich, St Louis, MO) were maintained in RPMI 1640 (HyClone, Logan, UT) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM glutamine. All cells were maintained in a 5% CO 2 atmosphere at 37 °C and trypsin-passaged at 80% confluence.
Mouse orthotopic neuroblastoma model
All mouse procedures were performed in accordance with the National Institute of Health protocols on Humane Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. The establishment of orthotopic neuroblastoma xenograft in a 7-week old female NCr nude mouse (Harlan, Indianapolis, IN) was previously described. 9 Briefly, the mouse was anesthetized with inhalational isoflurane. A transverse incision was made on the left flank to locate the left adrenal gland, and 2 μL of PBS containing 1 million KELLY cells were injected into the adrenal gland. The fascia and skin were closed in separate layers. Tumor formation was followed by noninvasive ultrasound measurements, and the animals were euthanized when the tumor volume exceeded 1,0 0 0 mm 3 . The tumor was harvested, embedded in paraffin, and sectioned for immunohistochemical staining with hematoxylin and eosin (H/E), Ki67, and TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay.
High-frequency ultrasound
After anesthetizing with inhalational isoflurane, the mouse was secured in a prone position, and a VisualSonics Vevo 2100 sonographic probe (Toronto, Ontario, Canada) was placed over the left flank to locate the left adrenal gland and the tumor. Serial crosssectional images (0.076 mm between images) were taken, and a 3-dimensional reconstruction tool (Vevo Software Version 1.6.0, Toronto, Ontario, Canada) was used to calculate the tumor volume.
Injection of vincristine-loaded silk fibroin gel into orthotopic neuroblastoma tumor
After the orthotopic neuroblastoma tumor reached 100 mm 3 by ultrasound, the mice were briefly anesthetized with inhaled isoflurane. Previous skin and fascial incisions were reopened to gain direct access to the adrenal gland or tumor. Sustained-release silk gel loaded with 50 μg of vincristine was injected into the tumor in either a single, central injection or distributed-injection pattern consisting of 8 points ( Fig 1 ) using a 28G insulin needle. Control mice with size-matched tumors were injected with silk gel not loaded with any drug either centrally or in the 8-point distributed pattern. The fascia and skin were closed in separate layers. Tumor formation was followed by noninvasive ultrasound measurements, and the animals were euthanized when the tumor volume exceeded 1,0 0 0 mm 3 .
Statistical analysis
Tumor sizes and postoperative days were entered into a scatter plot, and a curve of best fit with the associated equation was created for each animal. By entering the desired tumor size (50 0 mm 3 , 60 0 mm 3 , 70 0 mm 3 , or 80 0 mm 3 ) into the equation, we solved for the postoperative day using the "goal seek" function under the "what-if analysis" (Microsoft Excel Version 14.7.4, Redmond, WA). The postoperative days obtained were compared between different groups using Student t test. Cell death and proliferation were quantified by counting TUNEL and Ki67 positive cells per area on representative slides. Quantified cell death and proliferation among the groups were compared using Student t test.
Results
Drug release from silk gel
The amount of drug released from silk gel loaded with 50 μg of vincristine was measured in vitro ( Fig 2 ) . The platform released * Left kidney; dotted line, injection pass. r, radius; r , radius of silk gel deposit.
5.61 ± 2.49 μg of vincristine at 2 hours, 3.13 ± 1.36 μg at 5 hours, followed by an additional 5.11 ± 1.94 μg at 24 hours; 1.78 ± 0.46 μg on day 3; 0.82 ± 0.82 μg on day 7; 0.37 ± 0.48 μg on day 10; 0.14 ± 0.32 μg on day 14; and 0.77 ± 0.59 μg on day 22. The initial release on day 1 accounted for 27.70% ± 3.88% of the total drug loaded, with a more gradual release of vincristine after days 3-5. Nearly half (49.82% ± 1.82%) of the total vincristine amount was released in vitro by day 32.
Tumor growth
Neuroblastoma tumor injected with silk gel loaded with vincristine 50 μg at the center had decreased tumor growth compared with control gel (without drug) injected at the center ( P < .05). Tumor size reached 500 mm 3 in 7.3 ± 3.3 days vs 0.3 ± 0.9 days ( P = .02); reached 600 mm 3 in 8.6 ± 3.7 days vs 0.9 ± 1.1 days ( P = .02); reached 700 mm 3 in 9.8 ± 4.1 days vs 1.4 ± 1.2 days ( P = .02); and reached 800 mm 3 in 11 ± 4.4 days vs 2 ± 1.4 days ( P = .02), respectively ( Fig 3 , A ) .
Neuroblastoma tumor injected with silk gel loaded with vincristine 50 μg total at 8 separate locations within the tumor had decreased tumor growth compared with control gel injected at 8 different locations within the tumor ( P < .05): Tumor size reached 500 mm 3 in 8.7 ± 3.7 days vs 0.7 ± 0.2 days ( P = .02); reached 600 mm 3 in 10.2 ± 3.8 days vs 1.6 ± 02 days ( P = .02); reached 700 mm 3 in 11.6 ± 3.9 days vs 26 ± 0.3 days ( P = .02); and reached 800 mm 3 in 12.9 ± 3.9 days vs 3.5 ± 0.4 days ( P = .01), respectively ( Fig 3 , B ) .
Control tumors, treated with silk gel not loaded with any drug either centrally or in the distributed injection pattern, had similar growth patterns. There was no significant difference in the time for the control tumors to reach 500 mm 3 , 600 mm 3 , 700 mm 3 , or 800 mm 3 based on the injection pattern ( P = .5, .29, .20, and .15, respectively). There was no evidence of bleeding or disruption of the blood supply immediately after injection, regardless of injection pattern.
Tumors treated with silk gel loaded with vincristine 50 μg either centrally ( n = 5 mice) or divided into 8 separate locations ( n = 6 mice) within the tumor appeared to have a perod of minimal growth ( < 200 mm 3 over 3 days) followed by an increased rate of tumor growth ( > 200 mm 3 over 3 days). We defined the transition between these 2 growth patterns as the inflexion point. The inflexion point for the centrally treated tumors was at 6.6 ± 4.1 days after treatment; tumors treated at 8 locations reached the inflection point at 13.3 ± 3.9 days ( P < .05) ( Fig 4 ) . The tumor size at the inflection point was similar for both groups: 514.3 ± 165.8 mm 3 for the centrally treated tumors and 458.7 ± 234.4 mm 3 for the 8-point-treated tumors.
Histology
Mice were sacrificed after tumor volume reached > 1,0 0 0 mm 3 by ultrasound, and tumors treated with vincristine-loaded or control gel either centrally or at 8 different locations ( Fig 1 ) were embedded in paraffin, sectioned, and stained with H/E, Ki67, or TUNEL ( Fig 5 ) . H/E staining of tumor cells adjacent to the vincristine- loaded silk gel developed tumor necrosis, which was not found in tumor cells adjacent to the control gel ( Fig 5 , A and B ) . Both vincristine-loaded and control gel treated tumors had viable and typical small round blue cells of neuroblastoma. The Ki67 staining, a marker for proliferation, was positive, and the TUNEL assay indicated minimal apoptosis in the post-inflection point tumors ( Fig 5 , C ) . Because the tumors were harvested when the tumor size reached > 1,0 0 0 mm 3 , all groups had similar proportions of viable and apoptotic tumor cells ( Fig 5 , C ) . Vincristinetreated specimens had 252 ± 78 TUNEL-positive cells/mm 2 in the 8-point injection model compared with 185 ± 31 TUNEL-positive cells/mm 2 in the center injection model ( P = .238). There was no significant difference in the TUNEL-positive cells/mm 2 when comparing both vincristine groups with control groups (219 ± 64 vs 193 ± 81 cells/mm 2 , respectively; P = .559). The amount of proliferation by Ki67-positive cells per mm 2 was also similar between all groups: 6393 ± 1073 cells/mm 2 in the vincristine-treated groups compared with 6715 ± 446 cells/mm 2 in the control groups ( P = .514).
Discussion
We loaded vincristine into sustained-release silk gels and injected these materials within an orthotopic neuroblastoma tumor. Using this approach, we were able to decrease the tumor growth rate. In particular, injecting the equivalent total dose of vincristineloaded gel separately at 8 different locations within the tumor was superior to injecting the gel centrally, doubling the time to reach the inflexion point. Furthermore, assuming vincristine diffused over a spherical space from the gel, injecting vincristineloaded silk gel at 8 different locations within the tumor in effect split the total tumor volume by 1/8 and halved the diffusion radius ( V = 4/3 π r 3 ). The histologic examination by H/E indicated that tumor cell necrosis contributed to the decrease in tumor growth rate.
This study took advantage of observed tumor growth patterns. Orthotopic tumors, regardless of the drug delivery method, grew initially at a slow rate until the tumor mass reached a critical point. After this point, which we defined as the inflection point, tumor growth rate expanded to > 200 mm 3 over 3 days. This enabled us to see tumor responses to therapy at an earlier stage and thereby not have to rely on survival statistics. Our results indicated a doubling in the time for the tumor to reach its inflection point when the tumor volume was treated by 8 separate injections. The inflection point provided an additional variable, along with tumor size, that could be used to judge therapeutic response. On histologic examination there was no significant difference in the number of Ki67-positive or TUNEL-positive cells between either control or vincristine-treated groups, regardless of injection pattern. To evaluate growth kinetics, the histologic examination was performed after the tumors reached 1,0 0 0 mm 3 , which was long after the difference in growth rate was identified. The tumors exhibited a differential growth pattern initially, but given enough time, the tumors continue to grow through this intermediate dose of vincristine, yielding comparable histologic and immunostaining results as one might expect with viable tumor.
A vincristine dose of 50 μg was chosen based on previous work, which reported tumor growth suppression. 12 We previously found that higher concentrations of vincristine-loaded silk-based platforms could suppress tumor growth for up to 150 days. 9 Higher doses of vincristine were also associated with more side effects. We chose an intermediate dose that could still suppress tumor growth on a more feasable time scale and demonstrate the benefits of a distributed injection model. Furthermore, this dose of vincristine implanted intratumoraly has been found to yield higher intratumor drug concentrations and lower plasma drug concentrations than 50 μg vincristine administered intravenously. 9 The prior work supports the argument that local therapy can improve treatment outcomes by increasing the effect on the tumor while decreasing systemic toxicity.
KELLY cells were used to generate orthotopic tumor models based on previous work 8 that reported more rapid growth compared with other MYCN amplified and nonamplified lines. Drugloaded sustained release silk platforms were effective at decreasing tumor growth in all tested tumor lines; however, the KELLY orthotopic tumor model was chosen in this study as the most appropriate model for locally advanced tumors, given its aggressive growth.
We have previously loaded vincristine onto other sustainedrelease platforms, such as a silk wafer. 13 The silk gel represents a more versatile format in application, simply injecting through a needle. Although we accessed the tumors via an open incision, the distributed method of injecting drug-loaded silk gel could be easily adapted to a less invasive procedure. The potential advantage is even greater for pediatric patients, who could undergo sonographic or computed tomography-guided techniques to percutaneously inject drug-loaded silk gel with light sedation. These radiologic modalities can also be used to estimate tumor volume, and in combination with the drug release profile of the sustainedrelease platform, the tumor response can be predicted. 12 This intratumoral sustained-release approach can be further extended to include loading more than 1 chemotherapeutic drug, thus increasing the tumor cell death. 9 Because the drug was applied within the tumor, the resultant toxicity was more favorable than administering the drug intravenously. 9 Intratumoral implantation of drug-loaded sustained-release platform relies on diffusion for the drug to reach the tumor cells. Fick's law of diffusion, the same law that governs pulmonary gas exchange and can be used to calculate cardiac output, states that flux, F, is proportional to the concentration gradient, C, over a distance, x , and the diffusion coefficient, D : F = −D ∂C ∂x . 14,15 Drug delivery platforms are an active area of research, where configurations and delivery reservoirs are modeled and modified to improve release profiles. 15 The advantage of our model, however, depends on decreasing the diffusion distance by augmenting the geometry, not by changing the properties of the delivery platform. The additional injections using a small-gauge needle did not contribute to the difference in growth (eg, by causing more bleeding or tissue damage), as evident by the similar growth patterns of the control groups, regardless of the injection pattern. The result is slower tumor growth in a model that could be applicable with various (or multiple) drugs and platforms. Although our 8-point injection model was chosen for its ease of application based on a spherical tumor, the optimal pattern of injection could be different based on the initial geometry of the tumor.
There are few clinically used drug delivery systems, such as Norplant and Implanon, where drug diffuses from an implanted reservoir. 16 These implantable systems require a subsequent procedure for removal. 17, 18 Silk fibroin, however, degrades to peptides and amino acids via an enzymatic reaction, eliminating the need for subsequent removal procedures. 19 Silk fibroin-based material has been examined in numerous animal models and found to have minimal immunologic response and favorable degradation properties. [20] [21] [22] This distributed injection model could foreseeably be used to improve local drug delivery systems, as an alternative to neoadjuvant therapy for unresectable disease or as an adjunct to surgery when complete resection is not feasible.
Our previous work has found that chemotherapy-loaded, sustained-release silk platforms can achieve tumor growth suppression when implanted within the tumor. 9 By modifying the method of delivery to a distributed pattern throughout the tumor, we have found that we can improve tumor growth suppression by decreasing the diffusion distance. Future work will focus on modeling the optimal distribution pattern for sustained release silk gel injections, testing the effect of distributive injections using multiple chemotherapeutic agents, and transitioning this technique to a minimally invasive approach that can potentially be used clinically.
